{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Acute lung inflammation", "Aspirin", "Atorvastatin", "Cobra venom factor", "Complement"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "33046059", "DateCompleted": {"Year": "2021", "Month": "07", "Day": "13"}, "DateRevised": {"Year": "2021", "Month": "07", "Day": "13"}, "Article": {"ArticleDate": [{"Year": "2020", "Month": "10", "Day": "12"}], "Language": ["eng"], "ELocationID": ["263", "10.1186/s12890-020-01307-3"], "Journal": {"ISSN": "1471-2466", "JournalIssue": {"Volume": "20", "Issue": "1", "PubDate": {"Year": "2020", "Month": "Oct", "Day": "12"}}, "Title": "BMC pulmonary medicine", "ISOAbbreviation": "BMC Pulm Med"}, "ArticleTitle": "Pretreatment with atorvastatin ameliorates cobra venom factor-induced acute lung inflammation in mice.", "Pagination": {"StartPage": "263", "MedlinePgn": "263"}, "Abstract": {"AbstractText": ["The complement system plays a critical role as the pathogenic factor in the models of acute lung injury due to various causes. Cobra venom factor (CVF) is a commonly used complement research tool. The CVF can cause acute inflammation in the lung by producing complement activation components. Atorvastatin (ATR) is a 3-hydroxy-3-methylglutaryl coenzyme A inhibitor approved for control of plasma cholesterol levels. This inhibitor can reduce the acute pulmonary inflammatory response. However, the ability of ATR in treating acute lung inflammation caused by complement activation is still unknown. Therefore, we investigated the effect of ATR on lung inflammation in mice induced by activation of the complement alternative pathway in this study.", "ATR (10\u2009mg/kg/day via oral gavage) was administered for 7\u2009days before tail vein injection of CVF (25\u2009\u03bcg/kg). On the seventh day, all mice were sacrificed 1\u2009h after injection. The lung lobe, bronchoalveolar lavage fluid (BALF), and blood samples were collected. The myeloperoxidase (MPO) activity of the lung homogenate, the leukocyte cell count, and the protein content of BALF were measured. The levels of interleukin-6 (IL-6), tumor necrosis factor-\u03b1 (TNF-\u03b1), P-selectin, and Intercellular cell adhesion molecule-1 (ICAM-1) in BALF and serum were determined by enzyme-linked immunosorbent assay. The pathological change of the lung tissue was observed by hematoxylin and eosin staining. The deposition of C5b-9 in the lung tissue was detected by immunohistochemistry. The phosphorylation of NF-\u03baB p65 in the lung tissues was examined by immunohistochemistry and western blotting.", "The lung inflammation levels were determined by measuring the leukocyte cell numbers and protein content of BALF, the lung MPO activity, and expression and staining of the inflammatory mediators (IL-6 and TNF-\u03b1), and adhesion molecules (P-selectin and ICAM-1) for lung lesion. A significant reduction in the lung inflammation levels was observed after 7\u2009days in ATR pre-treated mice with a CVF-induced lung disease. Deposition of C5b-9 was significantly alleviated by ATR pretreatment. Early intervention with ATR significantly reduced the development of acute lung inflammation on the basis of phosphorylation of NF-\u03baB p65 in the lung.", "These findings suggest the identification of ATR treatment for the lung inflammation induced by activating the complement system on the basis of its anti-inflammatory response. Together with the model replicating the complement activating characteristics of acute lung injury, the results may be translatable to the overactivated complement relevant diseases."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, China."}, {"Identifier": [], "Affiliation": "Center for Pharmacology and Bioactivity Research, The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Sciences, Guiyang, 550014, China."}, {"Identifier": [], "Affiliation": "Modern Research Center for Traditional Chinese Medicine, Shanxi University, Taiyuan, 030006, China."}], "LastName": "Guo", "ForeName": "Jing", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "General Ward, Guizhou Provincial People's Hospital, Guiyang, 550002, China."}], "LastName": "Li", "ForeName": "Min", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Center for Pharmacology and Bioactivity Research, The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Sciences, Guiyang, 550014, China."}], "LastName": "Yang", "ForeName": "Yi", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Center for Pharmacology and Bioactivity Research, The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Sciences, Guiyang, 550014, China."}], "LastName": "Zhang", "ForeName": "Lin", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Modern Research Center for Traditional Chinese Medicine, Shanxi University, Taiyuan, 030006, China."}, {"Identifier": [], "Affiliation": "Key Laboratory of Chemical Biology and Molecular Engineering of Education Ministry, Institute of Molecular Science, Shanxi University, Taiyuan, 030006, China."}], "LastName": "Zhang", "ForeName": "Li-Wei", "Initials": "LW"}, {"Identifier": ["0000-0001-9691-2028"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, China. sunqy@hotmail.com."}, {"Identifier": [], "Affiliation": "Center for Pharmacology and Bioactivity Research, The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Sciences, Guiyang, 550014, China. sunqy@hotmail.com."}], "LastName": "Sun", "ForeName": "Qian-Yun", "Initials": "QY"}], "GrantList": [{"GrantID": "QKHJC[2017]1115", "Agency": "Guizhou Provincial Natural Science Foundation", "Country": ""}, {"GrantID": "QKHRC[2016]4018", "Agency": "Guizhou Provincial Natural Science Foundation", "Country": ""}, {"GrantID": "QKHPTRC[2016]5625", "Agency": "Guizhou Provincial Natural Science Foundation", "Country": ""}, {"GrantID": "QKHZC[2018]2828", "Agency": "Guizhou Provincial Natural Science Foundation", "Country": ""}, {"GrantID": "QKHPTRC[2019]5702", "Agency": "Guizhou Provincial Natural Science Foundation", "Country": ""}, {"GrantID": "U1812403", "Agency": "National Natural Science Foundation of China", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "BMC Pulm Med", "NlmUniqueID": "100968563", "ISSNLinking": "1471-2466"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Elapid Venoms"}, {"RegistryNumber": "0", "NameOfSubstance": "Inflammation Mediators"}, {"RegistryNumber": "0", "NameOfSubstance": "Tumor Necrosis Factor-alpha"}, {"RegistryNumber": "0", "NameOfSubstance": "cobra venom factor"}, {"RegistryNumber": "126547-89-5", "NameOfSubstance": "Intercellular Adhesion Molecule-1"}, {"RegistryNumber": "A0JWA85V8F", "NameOfSubstance": "Atorvastatin"}, {"RegistryNumber": "EC 1.11.1.7", "NameOfSubstance": "Peroxidase"}], "MeshHeadingList": [{"QualifierName": ["chemically induced", "drug therapy", "metabolism"], "DescriptorName": "Acute Lung Injury"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["administration & dosage", "pharmacology"], "DescriptorName": "Atorvastatin"}, {"QualifierName": [], "DescriptorName": "Bronchoalveolar Lavage Fluid"}, {"QualifierName": ["administration & dosage", "adverse effects"], "DescriptorName": "Elapid Venoms"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": ["metabolism"], "DescriptorName": "Inflammation Mediators"}, {"QualifierName": ["metabolism"], "DescriptorName": "Intercellular Adhesion Molecule-1"}, {"QualifierName": ["metabolism", "pathology"], "DescriptorName": "Lung"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": ["metabolism"], "DescriptorName": "Peroxidase"}, {"QualifierName": ["metabolism"], "DescriptorName": "Tumor Necrosis Factor-alpha"}], "CoiStatement": "The authors declare that they have no competing interests related to this publication."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Siempos II, Maniatis NA, Kopterides P, Magkou C, Glynos C, Roussos C, Armaganidis A. Pretreatment with atorvastatin attenuates lung injury caused by high-stretch mechanical ventilation in an isolated rabbit lung model. Crit Care Med. 2010;38:1321\u20131328. doi: 10.1097/CCM.0b013e3181d9dad6.", "ArticleIdList": ["10.1097/CCM.0b013e3181d9dad6", "20308883"]}, {"Citation": "Hammerschmidt DE, Weaver LJ, Hudson LD, Craddock PR, Jacob HS. Association of complement activation and elevated plasma-C5a with adult respiratory distress syndrome. Pathophysiological relevance and possible prognostic value. Lancet. 1980;1:947\u2013949. doi: 10.1016/S0140-6736(80)91403-8.", "ArticleIdList": ["10.1016/S0140-6736(80)91403-8", "6103300"]}, {"Citation": "Solomkin JS, Cotta LA, Satoh PS, Hurst JM, Nelson RD. Complement activation and clearance in acute illness and injury: evidence for C5a as a cell-directed mediator of the adult respiratory distress syndrome in man. Surgery. 1985;97:668\u2013678.", "ArticleIdList": ["4002115"]}, {"Citation": "Ward PA. Rous-Whipple award lecture. Role of complement in lung inflammatory injury. Am J Pathol. 1996;149:1081\u20131086.", "ArticleIdList": ["PMC1865199", "8863656"]}, {"Citation": "Mulligan MS, Schmid E, Beck-Schimmer B, Till GO, Friedl HP, Brauer RB, et al. Requirement and role of C5a in acute lung inflammatory injury in rats. J Clin Invest. 1996;98:503\u2013512. doi: 10.1172/JCI118818.", "ArticleIdList": ["10.1172/JCI118818", "PMC507456", "8755663"]}, {"Citation": "Abe M. Complement activation and inflammation. Rinsho Byori. 2006;54:744\u2013756.", "ArticleIdList": ["16913666"]}, {"Citation": "Li Y, Yang Z, Chavko M, Liu B, Aderemi OA, Simovic MO, et al. Complement inhibition ameliorates blast-induced acute lung injury in rats: potential role of complement in intracellular HMGB1-mediated inflammation. PLoS One. 2018;13:e0202594. doi: 10.1371/journal.pone.0202594.", "ArticleIdList": ["10.1371/journal.pone.0202594", "PMC6105023", "30133517"]}, {"Citation": "Gordon T. Role of the complement system in the acute respiratory effects of inhaled endotoxin and cotton dust. Inhal Toxicol. 1994;6:253\u2013266. doi: 10.3109/08958379408995235.", "ArticleIdList": ["10.3109/08958379408995235"]}, {"Citation": "Greene KE, Parsons PE. Complement and endotoxin in lung injury. Acute lung injury. Springer Berlin Heidelberg;1998.p.54\u201369."}, {"Citation": "Flierl MA, Rittirsch D, Sarma JV, Huber-Lang M, Ward PA. Adrenergic regulation of complement-induced acute lung injury. Adv Exp Med Biol. 2008;632:93\u2013103.", "ArticleIdList": ["19025117"]}, {"Citation": "Ehrnthaller C, Ignatius A, Gebhard F, Huber-Lang M. New insights of an old defense system: structure, function, and clinical relevance of the complement system. Mol Med. 2011;17:317\u2013329. doi: 10.2119/molmed.2010.00149.", "ArticleIdList": ["10.2119/molmed.2010.00149", "PMC3060978", "21046060"]}, {"Citation": "Vogel CW, Fritzinger DC. Cobra venom factor: structure, function, and humanization for therapeutic complement depletion. Toxicon. 2010;56:1198\u20131222. doi: 10.1016/j.toxicon.2010.04.007.", "ArticleIdList": ["10.1016/j.toxicon.2010.04.007", "20417224"]}, {"Citation": "Till GO, Johnson KJ, Kunkel R, Ward PA. Intravascular activation of complement and acute lung injury. Dependency on neutrophils and toxic oxygen metabolites. J Clin Invest. 1982;69:1126\u20131135. doi: 10.1172/JCI110548.", "ArticleIdList": ["10.1172/JCI110548", "PMC370177", "7068850"]}, {"Citation": "Ward PA, Till GO, Hatherill JR, Annesley TM, Kunkel RG. Systemic complement activation, lung injury, and products of lipid peroxidation. J Clin Invest. 1985;76:517\u2013527. doi: 10.1172/JCI112001.", "ArticleIdList": ["10.1172/JCI112001", "PMC423855", "4031060"]}, {"Citation": "Till GO, Ward PA. Systemic complement activation and acute lung injury. Fed Proc. 1986;45:13\u201318.", "ArticleIdList": ["3940902"]}, {"Citation": "Younger JG, Sasaki N, Delgado J, Ko AC, Nghiem TX, Waite MD, et al. Systemic and lung physiological changes in rats after intravascular activation of complement. J Appl Physiol. 1985;90:2289\u20132295. doi: 10.1152/jappl.2001.90.6.2289.", "ArticleIdList": ["10.1152/jappl.2001.90.6.2289", "11356794"]}, {"Citation": "Guo J, Li M, Yang FM, Sun QY. Inflammatory mechanism of acute lung injury in mice induced by activation of complement alternative pathway. Chin Pharmacol Bull. 2016;32:1521\u20131526."}, {"Citation": "Jiang L, Zhang L, Kang K, Fei D, Gong R, Cao Y, et al. Resveratrol ameliorates LPS-induced acute lung injury via NLRP3 inflammasome modulation. Biomed Pharmacother. 2016;84:130\u2013138. doi: 10.1016/j.biopha.2016.09.020.", "ArticleIdList": ["10.1016/j.biopha.2016.09.020", "27643555"]}, {"Citation": "Sch\u00f6nbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation. 2004;109:II18\u2013II26. doi: 10.1161/01.CIR.0000129505.34151.23.", "ArticleIdList": ["10.1161/01.CIR.0000129505.34151.23", "15173059"]}, {"Citation": "Chopra V, Flanders SA. Does statin use improve pneumonia outcomes? Chest. 2009;136:1381\u20131388. doi: 10.1378/chest.09-0941.", "ArticleIdList": ["10.1378/chest.09-0941", "19892677"]}, {"Citation": "Melo AC, Valen\u00e7a SS, Gitirana LB, Santos JC, Ribeiro ML, Machado MN, et al. Redox markers and inflammation are differentially affected by atorvastatin, pravastatin or simvastatin administered before endotoxin-induced acute lung injury. Int Immunopharmacol. 2013;17:57\u201364. doi: 10.1016/j.intimp.2013.05.016.", "ArticleIdList": ["10.1016/j.intimp.2013.05.016", "23747588"]}, {"Citation": "Craig T, O\u2019Kane C, McAuley D. Potential mechanisms by which statins modulate the development of acute lung injury. Intensive Care Medicine. Springer Berlin Heidelberg; 2007.p.276\u201388."}, {"Citation": "Singla S, Jacobson JR. Statins as a novel therapeutic strategy in acute lung injury. Pulm Circ. 2012;2:397\u2013406. doi: 10.4103/2045-8932.105028.", "ArticleIdList": ["10.4103/2045-8932.105028", "PMC3555410", "23372924"]}, {"Citation": "Souza-Costa DC, Figueiredo-Lopes L, Alves-Filho JC, Semprini MC, Gerlach RF, Cunha FQ, Tanus-Santos JE. Protective effects of atorvastatin in rat models of acute pulmonary embolism: involvement of matrix metalloproteinase-9. Crit Care Med. 2007;35:239\u2013245. doi: 10.1097/01.CCM.0000251638.67104.C3.", "ArticleIdList": ["10.1097/01.CCM.0000251638.67104.C3", "17133179"]}, {"Citation": "Sun QY, Chen G, Guo H, Chen S, Wang WY, Xiong YL. Prolonged cardiac xenograft survival in Guinea pig-to-rat model by a highly active cobra venom factor. Toxicon. 2003;42:257\u2013262. doi: 10.1016/S0041-0101(03)00140-5.", "ArticleIdList": ["10.1016/S0041-0101(03)00140-5", "14559076"]}, {"Citation": "Proctor LM, Strachan AJ, Woodruff TM, Mahadevan IB, Williams HM, Shiels IA, Taylor SM. Complement inhibitors selectively attenuate injury following administration of cobra venom factor to rats. Int Immunopharmacol. 2006;6:1224\u20131232. doi: 10.1016/j.intimp.2006.03.002.", "ArticleIdList": ["10.1016/j.intimp.2006.03.002", "16782534"]}, {"Citation": "Marashi SM, Hosseini SF, Hosseinzadeh M, Qadir MF, Khodaei F. Ameliorative role of aspirin in paraquat-induced lung toxicity via mitochondrial mechanisms. J Biochem Mol Toxicol. 2019;33:e22370. doi: 10.1002/jbt.22370.", "ArticleIdList": ["10.1002/jbt.22370", "31348582"]}, {"Citation": "de Paula TP, Santos PC, Arifa RDDN, et al. Treatment with atorvastatin provides additional benefits to imipenem in a model of gram-negative pneumonia induced by Klebsiella pneumoniae in mice. Antimicrob Agents Chemother. 2018;62:e00764\u2013e00717. doi: 10.1128/AAC.00764-17.", "ArticleIdList": ["10.1128/AAC.00764-17", "PMC5923152", "29463546"]}, {"Citation": "Goldblum SE, Wu KM, Jay M. Lung myeloperoxidase as a measure of pulmonary leukostasis in rabbits. J Appl Physiol. 1985;59:1978\u20131985. doi: 10.1152/jappl.1985.59.6.1978.", "ArticleIdList": ["10.1152/jappl.1985.59.6.1978", "3001018"]}, {"Citation": "Schingnitz U, Hartmann K, Macmanus CF, et al. Signaling through the A2B adenosine receptor dampens endotoxin-induced acute lung injury. J Immunol. 2010;184:5271\u20135279. doi: 10.4049/jimmunol.0903035.", "ArticleIdList": ["10.4049/jimmunol.0903035", "PMC2858788", "20348420"]}, {"Citation": "Asghar SS. Pharmacological manipulation of the complement system in human diseases. Front Biosci. 1996;1:e15\u2013e25. doi: 10.2741/A139.", "ArticleIdList": ["10.2741/A139", "9159241"]}, {"Citation": "Sarma JV, Ward PA. New developments in C5a receptor signaling. Cell Health Cytoskelet. 2012;4:73\u201382.", "ArticleIdList": ["PMC3619443", "23576881"]}, {"Citation": "Ward PA. Role of complement, chemokines, and regulatory cytokines in acute lung injury. Ann N Y Acad Sci. 1996;796:104\u2013112. doi: 10.1111/j.1749-6632.1996.tb32572.x.", "ArticleIdList": ["10.1111/j.1749-6632.1996.tb32572.x", "8906217"]}, {"Citation": "Sun SH, Wang HB, Zhao GY, An YB, Du LY, Song HB, et al. A role for complement in paraquat-induced acute lung injury. Mol Immunol. 2010;47:2212\u20132213. doi: 10.1016/j.molimm.2010.05.053.", "ArticleIdList": ["10.1016/j.molimm.2010.05.053"]}, {"Citation": "Wang RX, Xiao H, Guo RF, Li Y, Shen BF. The role of C5a in acute lung injury induced by highly pathogenic viral infections. Emerg Microbes Infect. 2015;4:e28.", "ArticleIdList": ["PMC4451266", "26060601"]}, {"Citation": "Sun S, Zhao G, Liu C, Wu X, Guo Y, Yu H, et al. Inhibition of complement activation alleviates acute lung injury induced by highly pathogenic avian influenza H5N1 virus infection. Am J Respir Cell Mol Biol. 2013;49:221\u2013230. doi: 10.1165/rcmb.2012-0428OC.", "ArticleIdList": ["10.1165/rcmb.2012-0428OC", "23526211"]}, {"Citation": "Heller A, Kunz M, Samakas A, Haase M, Kirschfink M, Koch T. The complement regulators C1 inhibitor and soluble complement receptor 1 attenuate acute lung injury in rabbits. Shock. 2000;13:285\u2013290. doi: 10.1097/00024382-200004000-00006.", "ArticleIdList": ["10.1097/00024382-200004000-00006", "10774617"]}, {"Citation": "Harkin DW, Marron CD, Rother RP, Romaschin A, Rubin BB, Lindsay TF. C5 complement inhibition attenuates shock and acute lung injury in an experimental model of ruptured abdominal aortic aneurysm. Br J Surg. 2005;92:1227\u20131234. doi: 10.1002/bjs.4938.", "ArticleIdList": ["10.1002/bjs.4938", "16078298"]}, {"Citation": "Mulligan MS, Smith CW, Anderson DC, Todd RF, 3rd, Miyasaka M, Tamatani T, et al. Role of leukocyte adhesion molecules in complement-induced lung injury. J Immunol. 1993;150:2401\u20132406.", "ArticleIdList": ["8095513"]}, {"Citation": "Bosmann M, Ward PA. Role of C3, C5 and anaphylatoxin receptors in acute lung injury and in sepsis. Adv Exp Med Biol. 2012;946:147\u2013159. doi: 10.1007/978-1-4614-0106-3_9.", "ArticleIdList": ["10.1007/978-1-4614-0106-3_9", "PMC3372066", "21948367"]}, {"Citation": "Zheng H, Liang W, He W, Huang C, Chen Q, Yi H, et al. Ghrelin attenuates sepsis-induced acute lung injury by inhibiting the NF-\u03baB, iNOS, and Akt signaling in alveolar macrophages. Am J Physiol Lung Cell Mol Physiol. 2019;317:L381\u2013L391. doi: 10.1152/ajplung.00253.2018.", "ArticleIdList": ["10.1152/ajplung.00253.2018", "31242025"]}, {"Citation": "Pandya PH, Wilkes DS. Complement system in lung disease. Am J Respir Cell Mol Biol. 2014;51:467\u2013473. doi: 10.1165/rcmb.2013-0485TR.", "ArticleIdList": ["10.1165/rcmb.2013-0485TR", "PMC4189484", "24901241"]}, {"Citation": "Thurman JM, Holers VM. The central role of the alternative complement pathway in human disease. J Immunol. 2006;176:1305\u20131310. doi: 10.4049/jimmunol.176.3.1305.", "ArticleIdList": ["10.4049/jimmunol.176.3.1305", "16424154"]}, {"Citation": "Tvedten HW, Till GO, Ward PA. Mediators of lung injury in mice following systemic activation of complement. Am J Pathol. 1985;119:92\u2013100.", "ArticleIdList": ["PMC1888073", "3985125"]}, {"Citation": "Trouw LA, Pickering MC, Blom AM. The complement system as a potential therapeutic target in rheumatic disease. Nat Rev Rheumatol. 2017;13:538\u2013547. doi: 10.1038/nrrheum.2017.125.", "ArticleIdList": ["10.1038/nrrheum.2017.125", "28794515"]}, {"Citation": "Bayly-Jones C, Bubeck D, Dunstone MA. The mystery behind membrane insertion: a review of the complement membrane attack complex. Philos Trans R Soc Lond Ser B Biol Sci. 2017;372(1726):20160221. doi: 10.1098/rstb.2016.0221.", "ArticleIdList": ["10.1098/rstb.2016.0221", "PMC5483522", "28630159"]}, {"Citation": "Chalmers JD, Short PM, Mandal P, Akram AR, Hill AT. Statins in community acquired pneumonia: evidence from experimental and clinical studies. Respir Med. 2010;104:1081\u20131091. doi: 10.1016/j.rmed.2010.04.005.", "ArticleIdList": ["10.1016/j.rmed.2010.04.005", "20447815"]}, {"Citation": "Jacobson JR, Barnard JW, Grigoryev DN, Ma SF, Tuder RM, Garcia JG. Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol. 2005;288:L1026\u2013L1032. doi: 10.1152/ajplung.00354.2004.", "ArticleIdList": ["10.1152/ajplung.00354.2004", "15665042"]}, {"Citation": "Li WC, Zou ZJ, Zhou MG, Chen L, Zhou L, Zheng YK, He ZJ. Effects of simvastatin on the expression of inducible NOS in acute lung injury in septic rats. Int J Clin Exp Pathol. 2015;8:15106\u201315111.", "ArticleIdList": ["PMC4713637", "26823851"]}, {"Citation": "Ren H, Ding M, Ma H, Yao Q, Zuo G, Xu Q, et al. c. Protective effects of combined use of atorvastatin and low molecular weight heparin on the inflammatory reaction and pulmonary functions in rats with sepsis. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2016;28:427\u2013432.", "ArticleIdList": ["29920039"]}, {"Citation": "Pinho-Ribeiro V, Melo AC, Kennedy-Feitosa E, Graca-Reis A, Barroso MV, Cattani-Cavalieri I, et al. Atorvastatin and simvastatin promoted mouse lung repair after cigarette smoke-induced emphysema. Inflammation. 2017;40:965\u2013979. doi: 10.1007/s10753-017-0541-5.", "ArticleIdList": ["10.1007/s10753-017-0541-5", "28251446"]}, {"Citation": "Jin SW, Zhang L, Lian QQ, Liu D, Wu P, Yao SL, Ye DY. Posttreatment with aspirin-triggered lipoxin A4 analog attenuates lipopolysaccharide-induced acute lung injury in mice: the role of heme oxygenase-1. Anesth Analg. 2007;104:369\u2013377. doi: 10.1213/01.ane.0000252414.00363.c4.", "ArticleIdList": ["10.1213/01.ane.0000252414.00363.c4", "17242094"]}, {"Citation": "Looney MR, Nguyen JX, Hu YM, Van Ziffle JA, Lowell CA, Matthay MA. Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury. J Clin Invest. 2009;119:3450\u20133461.", "ArticleIdList": ["PMC2769181", "19809160"]}, {"Citation": "Tilgner J, von Trotha KT, Gombert A, Jacobs MJ, Drechsler M, D\u00f6ring Y, et al. Aspirin, but not tirofiban displays protective effects in endotoxin induced lung injury. PLoS One. 2016;11:e0161218. doi: 10.1371/journal.pone.0161218.", "ArticleIdList": ["10.1371/journal.pone.0161218", "PMC5008681", "27583400"]}, {"Citation": "Hu X, Shen H, Wang Y, Zhang L, Zhao M. Aspirin-triggered resolvin D1 alleviates paraquat-induced acute lung injury in mice. Life Sci. 2019;218:38\u201346. doi: 10.1016/j.lfs.2018.12.028.", "ArticleIdList": ["10.1016/j.lfs.2018.12.028", "30571954"]}, {"Citation": "Erlich JM, Talmor DS, Cartin-Ceba R, Gajic O, Kor DJ. Prehospitalization antiplatelet therapy is associated with a reduced incidence of acute lung injury: a population-based cohort study. Chest. 2011;139:289\u2013295. doi: 10.1378/chest.10-0891.", "ArticleIdList": ["10.1378/chest.10-0891", "PMC3032365", "20688925"]}, {"Citation": "Kor DJ, Erlich J, Gong MN, Malinchoc M, Carter RE, Gajic O, et al. Association of prehospitalization aspirin therapy and acute lung injury: results of a multicenter international observational study of at-risk patients. Crit Care Med. 2011;39:2393\u20132400. doi: 10.1097/CCM.0b013e318225757f.", "ArticleIdList": ["10.1097/CCM.0b013e318225757f", "PMC3196806", "21725238"]}, {"Citation": "Kor DJ, Talmor DS, Banner-Goodspeed VM, Carter RE, Hinds R, Park PK, et al. Lung injury prevention with aspirin (LIPS-A): a protocol for a multicentre randomised clinical trial in medical patients at high risk of acute lung injury. BMJ Open. 2012;2:e001606. doi: 10.1136/bmjopen-2012-001606.", "ArticleIdList": ["10.1136/bmjopen-2012-001606", "PMC3437429", "22952165"]}, {"Citation": "Tuinman PR, Vlaar AP, Binnenkade JM, Juffermans NP. The effect of aspirin in transfusion-related acute lung injury in critically ill patients. Anaesthesia. 2012;67:594\u2013599. doi: 10.1111/j.1365-2044.2011.07054.x.", "ArticleIdList": ["10.1111/j.1365-2044.2011.07054.x", "22324349"]}, {"Citation": "Panka BA, de Grooth HJ, Spoelstra-de Man AM, Looney MR, Tuinman PR. Prevention or treatment of ARDS with aspirin: a review of preclinical models and meta-analysis of clinical studies. Shock. 2017;47:13\u201321. doi: 10.1097/SHK.0000000000000745.", "ArticleIdList": ["10.1097/SHK.0000000000000745", "PMC5175412", "27984533"]}, {"Citation": "Yu H, Ni YN, Liang ZA, Liang BM, Wang YM. The effect of aspirin in preventing the acute respiratory distress syndrome/acute lung injury: A meta-analysis. Am J Emerg Med. 2018;36:1486\u20131491. doi: 10.1016/j.ajem.2018.05.017.", "ArticleIdList": ["10.1016/j.ajem.2018.05.017", "29804790"]}]}], "History": [{"Year": "2020", "Month": "1", "Day": "31"}, {"Year": "2020", "Month": "10", "Day": "4"}, {"Year": "2020", "Month": "10", "Day": "13", "Hour": "5", "Minute": "27"}, {"Year": "2020", "Month": "10", "Day": "14", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "7", "Day": "14", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "10", "Day": "12"}], "PublicationStatus": "epublish", "ArticleIdList": ["33046059", "PMC7552367", "10.1186/s12890-020-01307-3", "10.1186/s12890-020-01307-3"]}}]}